Coherus BioSciences (CHRS) Reports Q4 Loss of $1.72/Share
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Coherus BioSciences (NASDAQ: CHRS) reported Q4 EPS of ($1.72), versus ($1.56) reported last year. Revenue for the quarter came in at $14.07 million, versus $6.87 million reported last year.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- KKR & Co. (KKR) Tops Q3 EPS Views
- DuPont (DD) Tops Q3 EPS by 14c; Boosts FY16 EPS Outlook; Says Continuing to Work with Regulators
- Wabash National (WNC) Tops Q3 EPS by 2c
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!